Complete Genomics Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2009 | $14 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Complete Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2009).
SEC Form D · Jul 2009
It delivers 1 product named in the sources below.
See Products and services
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2009
Products#
1 named by the sources below.
- Complete Genomics Data File Format
Wikidata · Wikidata: product or material produced (P1056)
Services#
No services of Complete Genomics Inc. are on record.
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| C. Thomas Caskey | Person | not stated | not stated | Held Series D and E preferred stock, director (Form 3, 2010) | SEC Form 3 |
| Enterprise Partners Management LLC | Fund or asset manager | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Enterprise Partners VI LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Enterprise Partners V L.P. | Fund or asset manager | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Essex Woodlands Health Ventures Fund VIII-A LP | Venture capital | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Essex Woodlands Health Ventures Fund VIII-B LP | Venture capital | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Essex Woodlands Health Ventures Fund VIII LP | Venture capital | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Highland Capital Management LP | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| OrbiMed Capital GP III LLC | Fund or asset manager | not stated | not stated | Held Series D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Ovp Venture Partners VI LP | Venture capital | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Prospect Management Co. III, L.L.C. | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Prospect Venture Partners III L.P. | Venture capital | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Strand Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Clifford A. Reid | Executive officer | Jul 2009 |
| Robert J. Curson | Executive officer | Jul 2009 |
| Alexander E. Barkas, Ph.D. | Director | Jul 2009 |
| Andrew Senyei, M.D. | Director | Jul 2009 |
| Charles P. Waite, Jr. | Director | Jul 2009 |
| Clifford A. Reid | Director | Jul 2009 |
About
Life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis.